Minnesota Oncology

Bone Cancer News

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Xgeva Safe and Effective for Giant Cell Tumor of the Bone (August 6, 2013)

The planned interim results of an international, open-label, phase 2 clinical trial published in the Lancet Oncology indicate that Xgeva® (denosumab) is safe and effective in the treatment of giant cell tumor of the bone. In fact, 96 percent of patients... Continue Reading

Xgeva Approved for Treatment of Giant Cell Tumor of the Bone (July 17, 2013)

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Xgeva® (denosumab) to include the treatment of adults and some adolescents with giant cell tumor of the bone (GCTB). Giant cell tumor of bone (GCTB) is a rare, aggressive, benign... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Xgeva Reduces Giant-cell Tumor of the Bone (October 2, 2012)

Xgeva® (denosumab) significantly reduced or eliminated tumor giant cells in patients with giant-cell tumor of the bone and also increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research. Giant cell... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Do Complementary Therapies Work? – Ask the expert about herbs, acupuncture, and other complementary therapies (November 4, 2011)

Live Web Chat with Barrie R. Cassileth, PhD, Chief, Integrative Medicine Service; Laurance S. Rockefeller Chair Integrative Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), click here for Dr. Cassileth’s bio Dr. Cassileth is a world-renowned... Continue Reading

Chemotherapy During Pregnancy Not Linked with Developmental Problems in Kids (October 4, 2011)

According to a study presented at the 2011 European Multidisciplinary Cancer Congress, children born to women who received chemotherapy during pregnancy do not appear to have an increased risk of heart or cognitive problems. Since relatively few women... Continue Reading

Latest Bone Cancer News By Stage


General Bone Cancer

Xgeva Safe and Effective for Giant Cell Tumor of the Bone (August 6, 2013)

The planned interim results of an international, open-label, phase 2 clinical trial published in the Lancet Oncology indicate that Xgeva® (denosumab) is safe and effective in the treatment of giant cell tumor of the bone. In fact, 96 percent of patients... Continue Reading

Xgeva Approved for Treatment of Giant Cell Tumor of the Bone (July 17, 2013)

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Xgeva® (denosumab) to include the treatment of adults and some adolescents with giant cell tumor of the bone (GCTB). Giant cell tumor of bone (GCTB) is a rare, aggressive, benign... Continue Reading

Xgeva Reduces Giant-cell Tumor of the Bone (October 2, 2012)

Xgeva® (denosumab) significantly reduced or eliminated tumor giant cells in patients with giant-cell tumor of the bone and also increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research. Giant cell... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Xgeva Delays Onset of Bone Metastases (September 27, 2011)

Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva™ (denosumab) delayed the spread of cancer to the bones. These results were presented at the 2011 European Multidisciplinary Cancer Conference. Androgen... Continue Reading

More General Bone Cancer